Why do so many scientists fail as entrepreneurs?
This is a guest post by Gerry Langeler, Managing Director with OVP Venture Partners. Do you have a response to Gerry’s […]
Why do so many scientists fail as entrepreneurs? Read Post »
This is a guest post by Gerry Langeler, Managing Director with OVP Venture Partners. Do you have a response to Gerry’s […]
Why do so many scientists fail as entrepreneurs? Read Post »
I have been struggling to understand the utility of Google Glass in most of the presented use cases. The Google Glass
Is the future of Google Glass in the life sciences? Read Post »
This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
ATMP in practice: Towards a new industry landscape in tissue engineering
Go to paperABSTRACT: Regulatory divergences and market fragmentation across member…
ATMP in practice: Towards a new industry landscape in tissue engineering Read Post »
The April 1 2014 issue of the Journal of Commercial Biotechnology has just been published, and features the following papers:
New issue of the Journal of Commercial Biotechnology Read Post »
New books from the publisher of the Journal of CommercialBiotechnology
Biomedical and health entrepreneurship continues to expand around the world. Driven by global pressures to optimize the allocation of scarce resources, life science bioentrepreneurs are creating innovative products, platforms, service and systems that …
Bioentrepreneurship Education and Training Trends Read Post »
The prospect of government regulation, product liability lawsuits, and customer reliance on third-party payers contribute to the complexity of valuing biotech start-ups. In addition, the inherent complexity of biologic drug manufacturing and storage creates secondary risks that must be considered in a valuation.
Considerations for Start-Up Biotech Company Valuation Read Post »
The purpose of this study was to test the unexplored relationship between market orientation (MO), alliance orientation (AO), and business performance (PERF) in the medical/healthcare subsector of the Canadian biotechnology industry. The study surveyed Canadian biotechnology executives via mail and web-based questionnaires. It was found that the relationship between MO and PERF was positive and significant and the relationship between AO and PERF was positive and significant. It was also found that the relationship between MO and AO was positive and significant, supporting the existence of a mediation relationship. Specifically, MO’s influence on PERF was found to be fully mediated by AO. This suggests that Canadian medical/healthcare biotechnology companies that were highly market-oriented were also highly alliance-oriented, and highly alliance-oriented companies were top performing companies. This study outlines the apparent sequential relationship between market-oriented behavioural commitments, alliance-oriented activities, and business performance outcomes among Canadian biotechnology companies. Furthermore, it has business development and the commercialization process implications for biotechnology managers.
This paper is an examination of the economics, organizational dynamics and structural factors inhibiting an electronic market for intellectual property. Several intermediaries exist to facilitate the transition of intellectual property (IP) from sellers to buyers. Over the past 20 years, a number of companies attempted to create an online “eBay for IP.” These IP Exchanges (IPEs) failed to gain traction in competition with other mediums that provide channels to facilitate IP transactions. Compounding the problem is the concentration of intellectual property assets amongst a small group of institutions and within those institutions as well as organizational hurdles inherent in academic technology transfer offices. As a result, the business model for an online IPE market is fundamentally challenging, and no successful IPE exists to date.
Abstract
The growing share of biopharmaceuticals is paralleled by an increasing interest in biogenerics, as blockbuster biologics are approaching their patent expiries. Companies need to make decisions whether to invest in biosimilars or in biobetters with enhanced properties, the latter enabling favorable differentiation vis-à-vis the original product on the one hand and biosimilars on the other hand. Net present value (NPV) modelling was applied to evaluate the financial attractiveness of two categories of biobetters in comparison to biosimilars, and recommendations are made which options should be preferred depending on a company’s business model.
Get new actionable insights and updates from BiotechBlog